Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2025

ETOP-IBCSG: Questions still unanswered in advanced NSCLC

Should we exclude immunotherapy in case of advanced NSCLC with oncogenic addiction?

Date

28 Mar 2025

Session

ETOP-IBCSG: Questions still unanswered in advanced NSCLC

Topics

Tumour Site

Non-Small Cell Lung Cancer

Presenters

JORDI REMON MASIP

Authors

J. REMON MASIP

Author affiliations

  • Institut Gustave Roussy, Villejuif/FR

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A and discussion

Session: ETOP-IBCSG: Questions still unanswered in advanced NSCLC

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.